Amerra Capital Management-owned Biomega sees a bright future for fish byproduct-based proteins for human consumption, and has developed an aggressive strategy to cash in on it.
Biomega believes fish byproducts will soon be used for direct human consumption rather than for fishmeal production. "Most people laugh at me when I say this," Biomega R&D Director Kartjan Sandnes said at the recent Marin Protein Nettverk summit.
Sandnes co-founded Biomega in 2000, but sold the company two years ago. Now he’s back, spearheading the group's global vision.
